moxifloxacin has been researched along with sertraline in 5 studies
Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (sertraline) | Trials (sertraline) | Recent Studies (post-2010) (sertraline) |
---|---|---|---|---|---|
3,157 | 552 | 1,690 | 3,480 | 1,028 | 1,329 |
Protein | Taxonomy | moxifloxacin (IC50) | sertraline (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.083 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.9848 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 2.7675 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 2.6309 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.8 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.5073 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.2888 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 1.4 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 1.2882 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 8.3173 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.1814 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 4.477 | |
D | Rattus norvegicus (Norway rat) | 0.26 | |
D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.8783 | |
Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.825 | |
D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 2.7409 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.083 | |
D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Homo sapiens (human) | 0.8 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.0016 | |
Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.1743 | |
Melanocortin receptor 5 | Homo sapiens (human) | 4.598 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 0.655 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 3.3935 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.2175 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 8.3173 | |
Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 8.3173 | |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0697 | |
Transporter | Rattus norvegicus (Norway rat) | 0.26 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Abbas, R; Bachinsky, M; Chappell, PB; Crownover, PH; Damle, B; LaBadie, RR; Riley, S | 1 |
1 review(s) available for moxifloxacin and sertraline
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for moxifloxacin and sertraline
Article | Year |
---|---|
A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Selective Serotonin Reuptake Inhibitors; Sertraline; Time Factors; Young Adult | 2020 |
3 other study(ies) available for moxifloxacin and sertraline
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |